Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

1. 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease

testing, field testing and/or after muscular strength testing 13 Figure 3a and 3b SCORE charts for European populations of countries at HIGH and LOW cardiovascular disease risk 15 Figure 4 Proposed algorithm for cardiovascular assessment in asymptomatic individuals with risk factors for and possible subclinical chronic coronary syndrome before engaging in sports for individuals aged >35 years 18 Figure 5 Clinical evaluation and recommendations for sports participation in individuals with established (...) Bicuspid aortic valve BMI Body mass index BP Blood pressure BrS Brugada syndrome CAC Coronary artery calcium CAD Coronary artery disease CCS Chronic coronary syndrome CCTA Coronary computed tomography angiography CHD Congenital heart disease CKD Chronic kidney disease CMD Coronary microvascular dysfunction CMR Cardiac magnetic resonance CPET Cardiopulmonary exercise test CPR Cardiopulmonary resuscitation CT Computed tomography CV Cardiovascular CVA Cerebrovascular accident CVD Cardiovascular disease

2020 European Society of Cardiology

2. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk

Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 Aug 18;76(7):781-793. doi: 10.1016/j.jacc.2020.06.040. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk , , , , , , , , , Affiliations Expand Affiliations 1 Emory

2020 EvidenceUpdates

3. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Full Text available with Trip Pro

in both groups across all categories of eGFR. Conclusions: In patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the range of renal function studied, with larger relative risk reductions in those with eGFR > 60 mL/min/1.73 m2. Keywords: Acute coronary syndrome; Chronic kidney disease; Glomerular filtration rate; Low-density lipoprotein cholesterol; Major adverse cardiovascular events; PCSK9 inhibition. © The Author(s) 2020. Published by Oxford (...) Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial - PubMed This site needs JavaScript to work properly. Please enable

2020 EvidenceUpdates

4. Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

published 23 Jul 2020 Circulation: Genomic and Precision Medicine. ;0 Abstract Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. However, not all cardiovascular practitioners are fully aware of the utility and potential pitfalls of incorporating genetic test results into the care of patients and their families (...) Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article

2020 American Heart Association

5. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Full Text available with Trip Pro

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Jun 9;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448. Epub 2020 Mar 28. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators COMPASS Steering

2020 EvidenceUpdates

6. Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Search Hello Guest! Login to your account Email Password Keep me logged (...) in Search Search 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association , MD, PhD, Chair , MD, FAHA, Co-chair , PhD, FAHA , MD, FAHA , MD, PhD , MD, PhD, FAHA , PhD, FAHA , MD, PhD, FAHA , PhD, FAHA , MD

2020 American Heart Association

7. Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial Full Text available with Trip Pro

Abstract Importance: Persons with serious mental illness have a cardiovascular disease mortality rate more than twice that of the overall population. Meaningful cardiovascular risk reduction requires targeted efforts in this population, who often have psychiatric symptoms and cognitive impairment. Objective: To determine the effectiveness of an 18-month multifaceted intervention incorporating behavioral counseling, care coordination, and care management for overall cardiovascular risk reduction (...) in adults with serious mental illness. Design, setting, and participants: This randomized clinical trial was conducted from December 2013 to November 2018 at 4 community mental health outpatient programs in Maryland. The study recruited adults with at least 1 cardiovascular disease risk factor (hypertension, diabetes, dyslipidemia, current tobacco smoking, and/or overweight or obesity) attending the mental health programs. Of 398 participants screened, 269 were randomized to intervention (132

2020 EvidenceUpdates

8. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. Full Text available with Trip Pro

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug (...) to 1.74).Our study confirmed previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospitalized with Covid-19. Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context. (Funded by the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.).Copyright © 2020

2020 NEJM

9. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. (Abstract)

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).To determine whether switching to ticagrelor monotherapy after 3 (...) with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09).Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor

2020 JAMA

10. Maternal cardiovascular risk after hypertensive disorder of pregnancy

Maternal cardiovascular risk after hypertensive disorder of pregnancy Maternal Cardiovascular Risk After Hypertensive Disorder of Pregnancy - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged (...) Actions . 2020 May 13;heartjnl-2020-316541. doi: 10.1136/heartjnl-2020-316541. Online ahead of print. Maternal Cardiovascular Risk After Hypertensive Disorder of Pregnancy , , , , , , , , Affiliations Expand Affiliations 1 Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 2 Cardiometabolic, George Institute for Global Health, Sydney, New South Wales, Australia. 3 Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 4 Medicine, University of New South Wales

2020 EvidenceUpdates

11. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Full Text available with Trip Pro

Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 28;dc192116. doi: 10.2337/dc19-2116. Online ahead of print. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study , , , , , , , , , , Affiliations Expand Affiliations

2020 EvidenceUpdates

12. Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic

Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic - American College of Cardiology ') Search All Types Search or Menu . This article was authored by Nicole M. Orr, MD, FACC , and the Geriatric Cardiology Council. Share via: Clinical Topics: Keywords: Aged, SARS Virus, Angiotensin Receptor Antagonists (...) , Hydroxychloroquine, Mineralocorticoid Receptor Antagonists, Caregivers, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Coronavirus, Coronavirus Infections, Neprilysin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neprilysin, Chloroquine, Subacute Care, Social Isolation, Skilled Nursing Facilities, Cardiovascular Diseases > > Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext

2020 American College of Cardiology

13. Covid-19 and cardiovascular disease. (Abstract)

Covid-19 and cardiovascular disease. Guideline: Diagnosis and management of cardiovascular disease during the covid-19 pandemicPublished by the European Society of Cardiology.This summary is based on the version published on 21 April 2020 (https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance).Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing

2020 BMJ

14. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. (Abstract)

Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Some studies, mainly from high-income countries (HICs), report that women receive less care (investigations and treatments) for cardiovascular disease than do men and might have a higher risk of death. However, very few studies systematically report risk factors, use of primary or secondary (...) prevention medications, incidence of cardiovascular disease, or death in populations drawn from the community. Given that most cardiovascular disease occurs in low-income and middle-income countries (LMICs), there is a need for comprehensive information comparing treatments and outcomes between women and men in HICs, middle-income countries, and low-income countries from community-based population studies.In the Prospective Urban Rural Epidemiological study (PURE), individuals aged 35-70 years from urban

2020 Lancet

15. Outcome and Cost of Optimal Control of Dyslipidemia in Adults with High Risk for Cardiovascular Disease

. Med. 2017; 167 : Itc81-itc96 World Health Organization. The World Health Report 2002: Quantifying Selected Major Risks to Health2002:49-97. Halcox J.P. Banegas J.R. Roy C. et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc. Disord. 2017; 17 : 160 Zwald ML, Akinbami LJ, Fakhouri TH, Fryar CD. Prevalence of Low High-density Lipoprotein Cholesterol Among Adults (...) of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc. Disord. 2014; 14 : 121 Sabatine M.S. Giugliano R.P. Keech A.C. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 2017; 376 : 1713-1722 Article Info Publication History Accepted: March 17, 2020 Received in revised form: February 28, 2020 Received: November 4, 2019 Publication stage In Press Journal Pre-Proof Identification DOI: Copyright © 2020 Published by Elsevier Inc

2020 Institute of Health Economics

16. Position Statement on Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic

Position Statement on Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic 1 Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement by the Cardiac Society of Australia and New Zealand Stephen J Nicholls 1 , Mark Nelson 2 , Carolyn Astley 3 , Tom Briffa 4 , Alex Brown 5 , Robyn Clark 3 , David Colquhoun 6 , Robyn Gallagher (...) care across the world. In addition to the described cardiovascular disease (CVD) complications of COVID-19, including myocarditis, myocardial injury, arrhythmia and thromboembolism, the pandemic has additional implications for the management of the patient with established atherosclerotic CVD. In particular, it provides challenges for the use and introduction of secondary prevention measures. This position statement provides recommendations for effective delivery of secondary prevention strategies

2020 Cardiac Society of Australia and New Zealand

17. Cardiovascular disease and COVID-19: Australian/New Zealand consensus statement

Abstract Introduction: The Coronavirus-19 disease (COVID-19) pandemic is caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Strategies to minimise the risk of viral transmission to healthcare workers and uninfected cardiac patients while prioritising high quality cardiac care are urgently needed. We conducted a rapid literature appraisal (...) 2 MI (28). Myocardial injury in COVID-19 patients can manifest with ST-elevation in the absence of obstructive coronary artery disease (CAD). Whether this is due to microvascular injury or myocarditis is unclear. To avoid unnecessary coronary angiography during the acute illness, haemodynamically stable patients with COVID-19 and possible MI may be best managed conservatively, with invasive procedures deferred until after COVID-19 recovery. Cardiovascular implications of novel therapies Numerous

2020 Cardiac Society of Australia and New Zealand

18. Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19

Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19 Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19 - American College of Cardiology ') Search All Types Search or Menu CBT=cognitive behavioral therapy; IV=intravenous; po=by mouth; SL=sublingually + People with Parkinsonism, Lewy body disease or pre-existing cogwheel rigidity, for whom haloperidol is contraindicated, quetiapine 12.5-25 mg orally up to 4 times daily can (...) to the surge in deaths in most communities. Bereavement support and acknowledgement of both our loss as clinicians, and the family's loss should be routine after a death. Provider Resiliency The cardiovascular care team is immersed on the front lines preparing for the surge of COVID-19 patients or already deeply engaged depending on location. Usual stress and long hours have been superseded by novel adversaries. Clinicians work lacking PPE in a new environment, with risks of COVID-19 illness and mortality

2020 American College of Cardiology

19. Key Questions on COVID-19 and Cardiovascular Disease

SQC Approval Date: April 24, 2020 Patients with cardiovascular conditions, especially poorly controlled disease, are at higher risk for COVID-19 complications. As such, they should be counseled to avoid situations that would put them at risk for SARS CoV2 exposure. They, along with their physician, should evaluate their workplace and determine if undue risk exists. If so, mitigation strategies should be considered. These include minimizing face-to-face contact between employees, assigning work (...) Syndrome X, Angina, Stable, Heart Defects, Congenital, Dyslipidemias, Geriatrics, Heart Failure, Angiography, Diagnostic Imaging, Pericarditis, Secondary Prevention, Hypertension, Pulmonary, Sleep Apnea Syndromes, Sports, Angina, Stable, Exercise Test, Heart Valve Diseases, Aneurysm, COVID-19, Coronavirus, Coronavirus Infections, Cardiology Magazine, ACC Publications > > Feature | Key Questions on COVID-19 and Cardiovascular Disease Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext. 5603

2020 American College of Cardiology

20. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry)

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

2020 EvidenceUpdates